OpGen, Inc. announced that it received a notice from The Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5250 due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024, which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq.
OpGen is a Maryland-based biotechnology company that researches and develops molecular diagnostic therapeutics for the treatment of infectious diseases.